Fino et al. demonstrated significantly higher CSF CHI3L1 levels in CIS and RRMS patients than in controls [55], suggesting the involvement of CHL3L1 in the pathogenesis of MS. This evidence concerns the gene CHI3L1 and in situ carcinoma.